Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Debio 0123 combinations in recurrent/progressive or newly diagnosed glioblastoma
2022-502156-31-00Phase 2Authorised
- Sponsor
- Debiopharm
- Start
- Apr 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of zedoresertib and temozolomide in glioblastoma (GBM) and astrocytoma (4 arms), sponsored by Debiopharm. Primary endpoints: Dose-limiting toxicities, Treatment-emergent adverse events and 8 more. Planned start Apr 2023; status: authorised.
02
Drugs
zedoresertibtemozolomide
03
Conditions
glioblastoma (GBM)astrocytoma
Beyond the preview
Go deeper on 2022-502156-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502156-31-00.